Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:56:57.886Z.
Calculation as of: 2026-10-06T18:56:57.886Z.
Quote observation: 2026-10-06T18:55:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.74B
PS Ratio
29.28
TTM Avg
24.70
3Y Avg
33.26
5Y Avg
69.19
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.80B | N/A | N/A | N/A | N/A |
| Xencor, Inc. (XNCR)vs › | $1.79B | 17.06 | 9.71 | 8.61 | 8.87 |
| Absci Corporation (ABSI)vs › | $1.78B | 1140.85 | 406.59 | 187.29 | 140.27 |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 6.92 | 8.80 | 8.75 | 8.05 |
| Novocure Ltd (NVCR)vs › | $1.78B | 2.54 | 2.44 | 3.04 | 7.36 |
| Novavax, Inc. (NVAX)vs › | $1.82B | 4.39 | 1.99 | 1.62 | 3.84 |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | 0.93 | 0.93 | 4.78 | 7.17 |
| Surgery Partners, Inc. (SGRY)vs › | $1.77B | 0.52 | 0.59 | 0.96 | 1.18 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.74B | 29.28 | 24.70 | 33.26 | 69.19 |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 0.48 | 0.49 | 0.90 | 1.14 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
